About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Galantamine Hydrobromide

Company: Northwell Health
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 5, 2026

Trial details

Recruiting NCT NCT04769206

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

Not yet reported, Not yet reported Vanderbilt University Medical Center 160 participants Est. completion 2028-06-01 1 site

Other conditions: Endothelial Dysfunction
View official trial listing →
Recruiting NCT NCT07003386

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

Not yet reported, Not yet reported Shanghai Yueyang Integrated Medicine Hospital 66 participants Est. completion 2028-09-30 1 site

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT07208344

Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease

Not yet reported Anhui Provincial Hospital 30 participants Est. completion 2026-06-30 1 site

Other conditions: Alzheimer Disease (AD)
View official trial listing →
Recruiting NCT NCT07284290

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

Not yet reported Virginia Commonwealth University 120 participants Est. completion 2029-11 1 site

Other conditions: Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
View official trial listing →
Recruiting NCT NCT07625332

Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

Not yet reported, Not yet reported Northwell Health 60 participants Est. completion 2027-12 3 sites Stand-alone

Metabolic syndrome Other conditions: Spinal Cord Injury, Traumatic Spinal Cord Injury, Paraplegia and Tetraplegia
View official trial listing →
Recruiting NCT NCT07633470

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Not yet reported Alpha Cognition, Inc 150 participants Est. completion 2027-04 22 sites

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00000172

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Not yet reported Janssen, LP 55 sites

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00035191

A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 254 participants Est. completion 2003-09

Other conditions: Dementia, Vascular
View official trial listing →
Completed NCT NCT00035204

A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 63 participants Est. completion 2003-05

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00077727

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 107 participants Est. completion 2005-02

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT00082602

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 83 participants Est. completion 2005-04

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00161044

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

Not yet reported University of Maryland, Baltimore 20 participants Est. completion 2005-09 1 site

Other conditions: Chronic Schizophrenia
View official trial listing →
Completed NCT NCT00164242

Treatment of Tardive Dyskinesia With Galantamine

Not yet reported Caroff, Stanley N., M.D. 36 participants Est. completion 2004-10 1 site

Other conditions: Tardive Dyskinesia
View official trial listing →
Completed NCT NCT00176423

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Not yet reported University of Maryland, Baltimore 117 participants Est. completion 2006-12 1 site

Other conditions: Schizophrenia, Schizoaffective Disorder
View official trial listing →
Completed NCT NCT00181636

Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

Not yet reported Massachusetts General Hospital 25 participants Est. completion 2006-10 1 site

Other conditions: Bipolar Disorder
View official trial listing →
Completed NCT NCT00181675

A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Not yet reported Massachusetts General Hospital 40 participants Est. completion 2003-09 1 site

Other conditions: ADHD
View official trial listing →
Completed NCT NCT00195845

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

Not yet reported Cambridge Health Alliance 30 participants Est. completion 2007-02 1 site

Other conditions: Bipolar Disorder
View official trial listing →
Status unknown NCT NCT00211588

Galantamine Executive Function in Parkinson's Disease

Not yet reported Memorial Hospital of Rhode Island 90 participants Est. completion 2007-05 1 site

Other conditions: Parkinson's Disease
View official trial listing →
Completed NCT NCT00216502

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Not yet reported Janssen-Cilag S.p.A. 254 participants Est. completion 2005-11

Other conditions: Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases
View official trial listing →
Completed NCT NCT00216515

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Not yet reported Janssen Korea, Ltd., Korea 102 participants Est. completion 2005-11

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00216593

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Not yet reported Janssen Pharmaceutica N.V., Belgium 415 participants Est. completion 2008-03

Other conditions: Dementia, Alzheimer Disease
View official trial listing →
Status unknown NCT NCT00219869

Galantamine in the Treatment of Post-Traumatic Headache

Not yet reported Rapoport, Alan, M.D. 30 participants Est. completion 2005-08 1 site

Other conditions: Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
View official trial listing →
Terminated NCT NCT00226824

Safety Study of Galantamine in Tic Disorders

Not yet reported Parkinson's Disease and Movement Disorders Center 1 participants Est. completion 2007-05 1 site

Other conditions: Tourette's Syndrome, Motor Tic Disorder, Vocal Tic Disorder
View official trial listing →
Completed NCT NCT00227994

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

Not yet reported University of Pittsburgh 40 participants Est. completion 2005-03 1 site

Other conditions: Cerebrovascular Accident
View official trial listing →
Completed NCT NCT00230997

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

Not yet reported Neurological Research Center 50 participants Est. completion 2004-08 5 sites

Other conditions: Lewy Body Disease
View official trial listing →
Terminated NCT NCT00232349

Efficacy of Galantamine to Treat Schizophrenia

Not yet reported Seattle Institute for Biomedical and Clinical Research 21 participants Est. completion 2007-06 1 site

Other conditions: Schizophrenia, Psychotic Disorder
View official trial listing →
Completed NCT NCT00234637

Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment

Not yet reported Novartis 204 participants Est. completion 2005-06 1 site

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00236431

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 1063 participants Est. completion 2003-12

Other conditions: Dementia, Alzheimer Disease
View official trial listing →
Completed NCT NCT00236574

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 974 participants Est. completion 2003-11

Other conditions: Dementia, Alzheimer Disease
View official trial listing →
Completed NCT NCT00240695

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 724 participants Est. completion 2004-05

Other conditions: Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
View official trial listing →
Completed NCT NCT00252603

Galantamine Versus Placebo in Childhood Autism

Not yet reported University of Medicine and Dentistry of New Jersey 20 participants Est. completion 2007-04 1 site

Other conditions: Autism, Childhood Autism
View official trial listing →
Completed NCT NCT00253188

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 653 participants Est. completion 1998-12

Other conditions: Alzheimer Disease, Dementia
View official trial listing →
Completed NCT NCT00253201

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 636 participants Est. completion 1997-10

Other conditions: Alzheimer Disease, Dementia
View official trial listing →
Completed NCT NCT00253214

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 973 participants Est. completion 2002-07

Other conditions: Alzheimer Disease, Dementia
View official trial listing →
Completed NCT NCT00253227

A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 387 participants Est. completion 1998-12

Other conditions: Alzheimer Disease, Dementia
View official trial listing →
Completed NCT NCT00261573

A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 593 participants Est. completion 2000-12

Other conditions: Alzheimer Disease, Vascular Dementia
View official trial listing →
Completed NCT NCT00283725

Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease

Ortho-McNeil Neurologics, Inc. 573 participants Est. completion 2006-12

Other conditions: Dementia, Alzheimer's Disease
View official trial listing →
Completed NCT NCT00291421

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease

Janssen Pharmaceutica N.V., Belgium 2360 participants Est. completion 2006-05

Other conditions: Alzheimer Disease, Dementia, Nervous System Diseases, Mental Disorders, Brain Diseases
View official trial listing →
Completed NCT NCT00297362

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Janssen Cilag Pharmaceutica S.A.C.I., Greece 344 participants Est. completion 2005-10

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00297414

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 1083 participants Est. completion 2005-01 144 sites

Other conditions: Mild Cognitive Impairment
View official trial listing →
Completed NCT NCT00299676

An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period

Janssen-Cilag Pty Ltd 61 participants Est. completion 2008-03 5 sites

Other conditions: Alzheimer Disease, Dementia, Galantamine
View official trial listing →
Completed NCT NCT00301574

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Not yet reported Janssen Pharmaceutical K.K. 398 participants Est. completion 2004-02

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00304629

Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 241 participants Est. completion 2002-03

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00309725

A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 139 participants Est. completion 1999-10

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00320736

Galantamine for Cognition in People With Schizophrenia

Not yet reported North Suffolk Mental Health Association 20 participants Est. completion 2006-05 1 site

Other conditions: Schizophrenia, Schizoaffective Disorder
View official trial listing →
Completed NCT NCT00338117

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 554 participants Est. completion 1997-05

Other conditions: Alzheimer's Disease, Dementia
View official trial listing →
Terminated NCT NCT00369603

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Not yet reported Duke University 4 participants Est. completion 2007-11 1 site Stand-alone

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00416169

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 41 participants Est. completion 2004-07

Other conditions: Frontotemporal Dementia, Pick Complex
View official trial listing →
Terminated NCT NCT00423969

Galantamine Augmentation of Escitalopram for Treatment of Depression

Not yet reported Indiana University 20 participants Est. completion 2005-09 1 site

Other conditions: Depression
View official trial listing →
Completed NCT NCT00463879

Galantamine for Cognitive Deficits in Schizophrenia

Not yet reported, Not yet reported Yale University 21 participants Est. completion 2007-09 1 site

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT00509067

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

Not yet reported Georgetown University 43 participants Est. completion 2011-03 1 site

Other conditions: Schizophrenia
View official trial listing →
Status unknown NCT NCT00523666

Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)

Not yet reported Ludwig-Maximilians - University of Munich 20 participants Est. completion 2008-09 1 site

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00551161

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

Not yet reported Northwell Health 12 participants Est. completion 2011-12 1 site

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00566735

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Not yet reported Massachusetts General Hospital 39 participants Est. completion 2008-01 1 site

Other conditions: Major Depression, Bipolar Depression, Schizoaffective Disorder
View official trial listing →
Completed NCT NCT00606801

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Not yet reported Yale University 34 participants Est. completion 2009-02 1 site

Other conditions: Cocaine Abuse
View official trial listing →
Status unknown NCT NCT00626613

The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)

Not yet reported Jinan Mental Hospital 1 site

Other conditions: Dementia, Alzheimer's Disease
View official trial listing →
Status unknown NCT NCT00637442

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Not yet reported University Hospital, Bonn 30 participants 1 site

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00645190

A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

Not yet reported Xian-Janssen Pharmaceutical Ltd. 215 participants Est. completion 2005-02

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT00645554

A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers

Not yet reported Xian-Janssen Pharmaceutical Ltd. 2 participants Est. completion 2004-09

Other conditions: Pharmacokinetics
View official trial listing →
Terminated NCT NCT00679627

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

Not yet reported Janssen Research & Development, LLC 2051 participants Est. completion 2012-05 95 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00741598

Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

Not yet reported Icahn School of Medicine at Mount Sinai 72 participants Est. completion 2014-05 2 sites

Other conditions: Bipolar Disorder
View official trial listing →
Completed NCT NCT00750529

Alzheimer and Sleep

Not yet reported University Hospital, Clermont-Ferrand 15 participants Est. completion 2013-09 2 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00809835

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Not yet reported Yale University 120 participants Est. completion 2015-01 2 sites

Other conditions: Cocaine Dependence
View official trial listing →
Completed NCT NCT00814658

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Not yet reported Janssen-Cilag Farmaceutica Ltda. 22 participants Est. completion 2009-10

Other conditions: Dementia
View official trial listing →
Completed NCT NCT00814801

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Not yet reported Janssen Pharmaceutical K.K. 580 participants Est. completion 2008-09 1 site

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00880412

A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease

Not yet reported Exonhit 197 participants Est. completion 2009-08 22 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT00969696

Galantamine Effects on Cognitive Function in Marijuana Users

Not yet reported Yale University 29 participants Est. completion 2011-07 1 site

Other conditions: Memory
View official trial listing →
Completed NCT NCT01009476

Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine

Janssen-Cilag G.m.b.H 1134 participants Est. completion 2008-08

Other conditions: Dementia, Alzheimer Disease, Dementia, Vascular
View official trial listing →
Completed NCT NCT01012167

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

Not yet reported University of Maryland, Baltimore 86 participants Est. completion 2014-07 6 sites

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT01023425

Clinical Trial of Donepezil Between the Naive Group and the Switching Group

Not yet reported Samsung Medical Center 72 participants Est. completion 2009-04 1 site

Other conditions: Alzheimer's Disease, Dementia
View official trial listing →
Completed NCT NCT01029132

Characteristics of Treatment Responders to Galantamine

Not yet reported Samsung Medical Center 66 participants Est. completion 2009-10 1 site

Other conditions: Dementia
View official trial listing →
Completed NCT NCT01039194

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Not yet reported Bristol-Myers Squibb 18 participants Est. completion 2010-04 1 site

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT01054976

The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

Not yet reported Janssen Korea, Ltd., Korea 99 participants Est. completion 2009-02

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT01100775

Effects of Galantamine on Cognition

Not yet reported University of Maryland, Baltimore 12 participants Est. completion 2014-08-21 1 site

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT01129479

Galantamine Treatment for Nonfluent Aphasia in Stroke Patients

Not yet reported University of North Carolina, Chapel Hill 8 participants Est. completion 2007-12

Cardiovascular disease Other conditions: Aphasia
View official trial listing →
Terminated NCT NCT01181921

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Not yet reported Janssen-Cilag, S.A. 1 participants Est. completion 2011-06 1 site

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT01190748

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Not yet reported Actavis Inc. 24 participants Est. completion 2004-12 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01190761

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

Not yet reported Actavis Inc. 24 participants Est. completion 2004-12 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01194336

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

U.S. Army Medical Research and Development Command 84 participants Est. completion 2012-10 1 site

Other conditions: Biomarkers, Pharmacological
View official trial listing →
Terminated NCT NCT01362686

Comparative Research of Alzheimer's Disease Drugs

Not yet reported Indiana University 200 participants Est. completion 2015-10 5 sites

Other conditions: Dementia, Alzheimer's Disease
View official trial listing →
Completed NCT NCT01372280

Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition

Not yet reported Dr. Reddy's Laboratories Limited 28 participants Est. completion 2004-11 Stand-alone

Other conditions: Fasting
View official trial listing →
Completed NCT NCT01372306

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition

Not yet reported Dr. Reddy's Laboratories Limited 24 participants Est. completion 2004-11 Stand-alone

Other conditions: Fed
View official trial listing →
Terminated NCT NCT01416948

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

Not yet reported INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium 32 participants Est. completion 2013-03 7 sites

Other conditions: Posttraumatic Stress Disorder, Traumatic Brain Injury
View official trial listing →
Completed NCT NCT01417429

Galantamine Effects on Nicotine Responses in Smokers

Not yet reported Yale University 12 participants Est. completion 2011-03 1 site

Other conditions: Smoking, Tobacco Withdrawal
View official trial listing →
Completed NCT NCT01478633

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Not yet reported Janssen Pharmaceutical K.K. 102 participants Est. completion 2013-06 11 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT01508494

Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment

Not yet reported Institut National de la Santé Et de la Recherche Médicale, France 47 participants Est. completion 2016-06-22 1 site

Cardiovascular disease Other conditions: Cognitive Impairment
View official trial listing →
Completed NCT NCT01529619

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Not yet reported Novartis Pharmaceuticals 52 participants Est. completion 2013-12 11 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT01531153

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

Not yet reported Yale University 93 participants Est. completion 2016-06 1 site

Other conditions: Addiction
View official trial listing →
Completed NCT NCT01548638

Effect of Galantamine on Smoking Abstinence

Not yet reported University of Pennsylvania 13 participants Est. completion 2013-10 1 site Stand-alone

Other conditions: Nicotine Addiction
View official trial listing →
Completed NCT NCT01669538

Effect of Galantamine on Short-term Abstinence

Not yet reported University of Pennsylvania 98 participants Est. completion 2017-11 1 site Stand-alone

Other conditions: Tobacco Use Disorder
View official trial listing →
Completed NCT NCT01677754

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Not yet reported Hoffmann-La Roche 542 participants Est. completion 2015-06-12 142 sites

Other conditions: Alzheimer's Disease
View official trial listing →
Status unknown NCT NCT01696591

The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

Duk Lyul Na 14 participants Est. completion 2013-09 1 site

Other conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Mental Disorders
View official trial listing →
Completed NCT NCT01734395

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

Janssen Korea, Ltd., Korea 1882 participants Est. completion 2008-01

Other conditions: Alzheimer's Disease
View official trial listing →
Terminated NCT NCT01852110

Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

Not yet reported Merck Sharp & Dohme LLC 240 participants Est. completion 2016-04-11

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT01872598

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Not yet reported AB Science 721 participants Est. completion 2020-12 6 sites

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT01880099

A Study to Help People Quit Smoking.

Not yet reported Yale University 60 participants Est. completion 2015-12 1 site

Other conditions: Nicotine Dependence
View official trial listing →
Completed NCT NCT01921972

The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease

Not yet reported Charite University, Berlin, Germany 232 participants Est. completion 2009-05

Other conditions: Alzheimer's Disease
View official trial listing →
Completed NCT NCT01944436

A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease

Sunnybrook Health Sciences Centre 57 participants Est. completion 2016-01 1 site

Other conditions: Lewy Body Disease
View official trial listing →
Completed NCT NCT01951118

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

Not yet reported New York State Psychiatric Institute 121 participants Est. completion 2019-05 1 site

Other conditions: Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
View official trial listing →
Completed NCT NCT02035982

Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease

Not yet reported Sunnybrook Health Sciences Centre 40 participants Est. completion 2015-09 2 sites

Other conditions: Alzheimer's Disease, Dementia
View official trial listing →
Status unknown NCT NCT02098824

Symptomatic Treatment of Vascular Cognitive Impairment

Not yet reported, Not yet reported Amsterdam UMC, location VUmc 30 participants Est. completion 2017-07 1 site

Other conditions: Mild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular), Vascular Dementia
View official trial listing →
Completed NCT NCT02187276

The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia

Federal University of Minas Gerais 129 participants Est. completion 2013-03

Other conditions: Alzheimer Disease, Late Onset
View official trial listing →
Terminated NCT NCT02234752

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

Not yet reported Sheppard Pratt Health System 3 participants Est. completion 2016-07 1 site

Other conditions: Schizophrenia, Schizoaffective Disorder
View official trial listing →
Completed NCT NCT02283242

Galantamine Effects in Patients With Metabolic Syndrome

Not yet reported University of Sao Paulo 60 participants Est. completion 2017-02 1 site

Metabolic syndrome
View official trial listing →
Completed NCT NCT02365285

Racial Differences in Vagal Control of Glucose Homeostasis

Not yet reported, Not yet reported Vanderbilt University Medical Center 23 participants Est. completion 2017-10-05 1 site

Other conditions: Obesity
View official trial listing →
Terminated NCT NCT02374567

Pharmacovigilance in Gerontopsychiatric Patients

Not yet reported Hannover Medical School 407 participants Est. completion 2017-06-28 5 sites

Other conditions: Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
View official trial listing →
Completed NCT NCT02420327

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Not yet reported University of Maryland, Baltimore 43 participants Est. completion 2017-03 1 site

Other conditions: Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
View official trial listing →
Completed NCT NCT02703636

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Not yet reported Novartis Pharmaceuticals 118 participants Est. completion 2018-05-07 19 sites

Other conditions: Mild to Moderate Alzheimer's Disease
View official trial listing →
Completed NCT NCT02872857

Subarachnoid Hemorrhage Recovery And Galantamine

Not yet reported, Not yet reported The University of Texas Health Science Center, Houston 60 participants Est. completion 2019-07-20 2 sites

Other conditions: Subarachnoid Hemorrhage
View official trial listing →
Withdrawn NCT NCT03014323

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

Not yet reported Vanderbilt University Medical Center Est. completion 2018-12 1 site

Other conditions: Insulin Sensitivity, Oxidative Stress
View official trial listing →
Active, not recruiting NCT NCT03124355

Vagal Stimulation in POTS

Not yet reported Vanderbilt University Medical Center 11 participants Est. completion 2027-12 1 site Stand-alone

Other conditions: Postural Tachycardia Syndrome
View official trial listing →
Completed NCT NCT03384784

Effect of Galantamine on Inflammation and Cognition

Not yet reported University of Pennsylvania 63 participants Est. completion 2022-05-31 1 site Stand-alone

Other conditions: HIV Associated Cognitive Motor Complex
View official trial listing →
Not yet recruiting NCT NCT03454646

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Not yet reported University Hospital, Bordeaux 1205 participants Est. completion 2027-09-15 31 sites

Other conditions: Alzheimer Disease, Cholinesterase Inhibitors
View official trial listing →
Completed NCT NCT03547622

Galantamine and CBT4CBT Pilot to Prevent Relapse.

Not yet reported Yale University 6 participants Est. completion 2019-02-28 1 site

Other conditions: Methadone or Buprenorphine Detoxoxification
View official trial listing →
Completed NCT NCT03565809

Quality of the Management of Diabetes in Elderly People With Dementia in France

University Hospital, Toulouse 87816 participants Est. completion 2018-12-31 1 site

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT05102045

The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Not yet reported Istanbul Medipol University Hospital 27 participants Est. completion 2017-06-01 1 site

Other conditions: Alzheimer Disease
View official trial listing →
Completed NCT NCT05321680

Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)

Not yet reported Centro Hospitalar De São João, E.P.E. 16 participants Est. completion 2022-03-20 1 site

Other conditions: Dementia
View official trial listing →
Not yet recruiting NCT NCT05564169

Masitinib in Patients With Mild Alzheimer's Disease

Not yet reported AB Science 600 participants Est. completion 2029-12 9 sites

Other conditions: Alzheimer Disease
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07625332

Also known as: Galantamine Hydrobromide, Galantamine Hydrobromide Extended Release, Razadyne ER

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.